References
- Slavin R, Jimenez P. Letter to the Editor. J Asthma 2009; 46:102–103.
- Steiß JO, Strohner P, Zimmer KP, Lindemann H. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008; 45:233–236.
- Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Recombinant humanized mAb-E25, an anti-IgE mAb, in birchpollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253–259.
- Casale TB, Bernstein IL, Busse WW. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110–121.
- Hayashi N, Tsukamoto Y, Sallas WM. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548–561.
- Hamilton RG, Marcotte GV, Saini S. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005; 303:81–91.
- Lowe P, Tannebaum S, Gautier A, Massanari M, Panahloo Z. Omalizumab (Xolair) may normalize IgE production rate in patients with moderate-to-severe atopic asthma. J Allergy Clin Immunol 2009; 123(2 Suppl 1):S152.